Sonnet BioTherapeutics Holdings Overview
Valuation check: SONN's ROE is -149.36%, below the Consumer Staples sector average of 14.21%.
Get informed when a big investor buys or sells
+ Follow-149.36%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SONN is -149.36%. That is below the Consumer Staples sector average of 14.21%. Investors often review this figure alongside Sonnet BioTherapeutics Holdings's historical trend and sector peers before judging valuation or financial health.
Against Consumer Staples companies, SONN currently prints -149.36% for ROE, while the sector average sits near 14.21%. That is roughly 1150.8% below the sector mean. Large gaps often invite a closer look at Sonnet BioTherapeutics Holdings's growth, margins, and balance sheet.
Return on Equity shows how effectively Sonnet BioTherapeutics Holdings converts resources into returns. At -149.36%, SONN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SONN's ROE (-149.36%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Sonnet BioTherapeutics Holdings's ROE against similar Consumer Staples names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Staples companies and their key multiples and fundamentals.
